BioSpace News Archive

Although Sophiris Bio plans to continue development, investors weren’t enthused, letting stock plunge more than 38 percent after the company released mixed results from its Phase IIb clinical trial of topsalysin in prostate cancer.

Are you reluctant to bring up a salary increase over the holiday season? Don’t be! In fact, the holidays are an excellent time to ask your employer for a promotion, and here’s why.

For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.

Following the announcement of positive results from Janssen’s Phase III open label long- term extension study, which evaluates the efficacy and safety data of Stelara in Crohn’s Disease (CD),

Maintaining a high negative pressure in airborne infection isolation rooms of hospitals (over -10 Pa) and in renovation sites (over -5 Pa) effectively limits the dispersion of airborne contaminants and dust, a new study from the University of Eastern Finland shows.

Days before Christmas, three new companies decided to strip away the wrapping paper and unveil themselves to the world. Each of the companies launched with millions of dollars raised through a Series A financing round.

Rudy Tanzi, Chair of the Cure Alzheimer’s Fund Research Leadership Group and the Kennedy Professor of Neurology at Harvard University and at Massachusetts General Hospital, and Rob Fried, CEO of ChromaDex, took time to speak with BioSpace about the current understanding of Alzheimer’s and some interesting approaches to drug development.

PhaseBio Pharmaceuticals, Inc.(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the appointment of Edmund P. Harrigan, M.D. to its board of directors, effective December 13, 2018.

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules

Phio Pharmaceuticals Corp., announced that Dr. Gerrit Dispersyn, President and Chief Operating Officer, will present at Biotech Showcase™ 2019, to be held January 7 – 9, 2019 at the Hilton San Francisco Union Square.